646 related articles for article (PubMed ID: 30862450)
1. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
2. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
[TBL] [Abstract][Full Text] [Related]
3. The tumour microenvironment and immune milieu of cholangiocarcinoma.
Fabris L; Perugorria MJ; Mertens J; Björkström NK; Cramer T; Lleo A; Solinas A; Sänger H; Lukacs-Kornek V; Moncsek A; Siebenhüner A; Strazzabosco M
Liver Int; 2019 May; 39 Suppl 1(Suppl 1):63-78. PubMed ID: 30907492
[TBL] [Abstract][Full Text] [Related]
4. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium.
Gentilini A; Pastore M; Marra F; Raggi C
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249019
[TBL] [Abstract][Full Text] [Related]
5. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
9. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
Høgdall D; Lewinska M; Andersen JB
Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P; Robert ME; Zhang X
Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187
[TBL] [Abstract][Full Text] [Related]
12. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
13. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
[TBL] [Abstract][Full Text] [Related]
15. Immune contexture of cholangiocarcinoma.
Paillet J; Kroemer G; Pol JG
Curr Opin Gastroenterol; 2020 Mar; 36(2):70-76. PubMed ID: 31895228
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblasts in cholangiocarcinoma.
Vaquero J; Aoudjehane L; Fouassier L
Curr Opin Gastroenterol; 2020 Mar; 36(2):63-69. PubMed ID: 31934895
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
[TBL] [Abstract][Full Text] [Related]
18. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
19. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
Zanetti M
J Immunol; 2015 Mar; 194(5):2049-56. PubMed ID: 25710958
[TBL] [Abstract][Full Text] [Related]
20. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine.
Casadio M; Biancaniello F; Overi D; Venere R; Carpino G; Gaudio E; Alvaro D; Cardinale V
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
